A Phase 2/3 interventional study of Interferon-ß-1b and Interferon ß-1b in Multiple Sclerosis, sponsored by S. Andrea Hospital. Completed at 1 site in Italy. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by S. Andrea Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.
Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 141st largest by enrollment of the 230 interventional ones that give a count, is one of 4 that started in 2005, is one of 4 in phase 2/3, and was the 10th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
University of Catania · Sites in Italy
Ages 20–40 · Healthy volunteers
Ciceri Fabio · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18–65
Sanofi · Sites in Italy, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 40 · Phase 3 66 · Phase 4 19
First in 1999; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 115 across the 230 interventional studies, 214 across the 59 observational. Of the 164 that completed or were terminated, 77 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 289 have an industry lead sponsor. The 10 most frequent:
S. Andrea Hospital is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
S. Andrea Hospital has 8 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT05748015Istituti Clinici Scientifici Maugeri SpADefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis | 2026-11-30 |
| NCT07502066IRCCS San Camillo, Venezia, ItalyClinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases | 2026-12 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 289 studies in Multiple Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The therapy with Interferon-ß-1b reduces the inflammatory component of multiple sclerosis with positive effects on the disease course. The 8 MUI dose at alternate days is kept constant for years. About 1/3 of patients suspend treatment by three years due to side effects or suspected or accepted ineffectiveness. The main objective of the study is to verify the safety and effectiveness of a cyclical administration (a month of suspension after two of treatment) from the beginning of treatment. There is the possibility that a scheme envisaging therapy free intervals can reduce the onset of negative feedbacks (antagonising the drug therapeutic effect) compared to the standard administration protocol. This might also result in an increase of the drug effectiveness and/or in a longer duration of effectiveness itself. Finally, cyclical administration allows patients to spend actual periods of "therapeutic vacation", with positive psychological effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interferon ß-1b Treatment by Cyclical Administration
Drug: Interferon-ß-1b
Interferon ß-1b Treatment
Drug: Interferon ß-1b
250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
250 micrograms (8 MIU) administered subcutaneously (sc) every other day
number of gad-enhancing lesions (CELs) in T1
Group (cyclic withdrawal vs full regimen) differences in the cumulative number of CELs
Time frame: baseline and after 12 months
number of new and enlarging T2 lesions
Group (cyclic withdrawal vs full regimen) differences in new and enlarging T2 lesions
Time frame: baseline and after 12 months
volume of T1 lesions (black holes)
Group (cyclic withdrawal vs full regimen) differences in T1 lesion volume (black holes)
Time frame: baseline and after 12 months
relapse rate
Group (cyclic withdrawal vs full regimen) differences in relapse rate
Time frame: baseline and after 12 months
Ran from Nov 2005 to primary completion in Aug 2010, 57 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
S. Andrea Hospital